Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
April 29, 2026
Neuroscience Today—April 29, 2026
April 29, 2026
Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership
April 28, 2026
Obesity Today—April 28, 2026
April 28, 2026
Endocrinology Today—April 28, 2026
April 28, 2026
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
April 28, 2026
AI in Healthcare and Digital Health Today—April 28, 2026
April 27, 2026
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
April 27, 2026
Hematology Today—April 27, 2026
April 27, 2026
Oncology Today—April 27, 2026
April 27, 2026
Lucid Diligence Brief: Sun Pharma acquisition of Organon
April 26, 2026
Lucid Diligence Brief: Regeneron Otarmeni FDA approval
April 25, 2026